Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Status Completed

Clinical Trial Summary

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine whether denosumab therapy either increases the disease control rate at 4 months in patients with recurrent measurable osteosarcoma as compared to historical Children's Oncology Group (COG) experience or denosumab therapy produces an objective response rate greater than 5% (Cohort 1). II. To determine whether denosumab therapy increases the disease control rate at 12 months in patients with recurrent resected osteosarcoma as compared to historical COG experience (Cohort 2). SECONDARY OBJECTIVES: I. To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of denosumab in subjects with recurrent osteosarcoma. II. To describe the tolerability of denosumab in subjects with recurrent osteosarcoma. III. To report the disease control rate and objective response rate for patients with recurrent osteosarcoma limited to bone. IV. To investigate biological markers potentially associated with response to denosumab in patients with recurrent osteosarcoma. OUTLINE: Patients receive denosumab subcutaneously (SC) on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up monthly for 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02470091
Study type	Interventional
Source	Children's Oncology Group
Contact
Status	Completed
Phase	Phase 2
Start date	November 21, 2015
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06041490` - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	Phase 2
Not yet recruiting	`NCT05515068` - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Completed	`NCT00093821` - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors	Phase 1
Active, not recruiting	`NCT03233204` - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT01553539` - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00091182` - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment	Phase 2
Completed	`NCT00004078` - Irinotecan in Treating Children With Refractory Solid Tumors	Phase 2
Completed	`NCT00004241` - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Phase 1
Active, not recruiting	`NCT04284774` - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03213678` - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT04668300` - Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma	Phase 2
Completed	`NCT01016015` - Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Phase 2
Completed	`NCT01807052` - Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas	N/A
Active, not recruiting	`NCT03698994` - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Not yet recruiting	`NCT03205644` - VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04320888` - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Completed	`NCT00030667` - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood	Phase 2
Active, not recruiting	`NCT02867592` - Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Phase 2